A major pharmaceutical company producing a widely used diabetes and weight-loss medication is facing growing demands to expand its product portfolio ahead of a critical shareholder meeting. Investors and analysts are questioning whether the company’s heavy reliance on a single blockbuster drug leaves it vulnerable to market shifts, regulatory risks, or competition. With the drug’s popularity driving both revenue and scrutiny, stakeholders are pushing for clearer plans to develop new treatments to secure long-term stability. The upcoming shareholder discussion could reveal how seriously the company is addressing these concerns.
Ozempic maker is under pressure to diversify as it prepares to face shareholders on Monday
